Tekmira seeks to dismiss Alnylam's patent suit alleging siRNA patent infringement
This article was originally published in Scrip
Executive Summary
Tekmira Pharmaceuticals, the Vancouver, BC-based developer of RNA interference (RNAi) therapeutics, has responded to a patent infringement suit filed by competitor Alnylam Pharmaceuticals on 17 January 2012 in the US District Court for the District of Massachusetts relating to using small interfering RNA (siRNA) in a drug development deal.